Home » Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering

Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering

Mar 09, 2000
Premium

R

EDWOOD CITY, Calif.--Maxygen announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute for pharmaceutical protein development. In the three-year deal, the company will apply its MolecularBreed-ing directed evolution technologies to the development of novel protein pharmaceuticals for cancer treatments. NCI will provide expertise in characterizing and evaluating the proteins for therapeutic potential. The specific target proteins and indications were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

What's Popular?

In Informatics

  1. Hearst Invests $75M in M2Gen

  2. Researchers Identify SNP Set, Develop QR Code to Distinguish Genome Samples

  3. Optalysys Raises $4M in Seed Funding Round

  4. Agena Bioscience, Molecular Health Partner for MassArray Interpretation

  5. NSGC Panelists Discuss Strategies to Convert Variants of Unknown Significance to Known Significance

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.